PMV Pharma Q2 FY26 net loss narrows 14.73% to $18.09 million

• PMV Pharmaceuticals posted a net loss of $18.09 million in the quarter ended June 30, 2026, narrowing from $21.21 million a year earlier.
• Operating loss improved to $18.88 million from $22.88 million, as operating expenses fell 17.47% to $18.88 million.
• Research and development expense dropped 20.24% to $14.68 million; general and administrative costs edged down 6.12% to $4.21 million.
• Interest income, net slid 53.37% to $788,000; cash, cash equivalents and marketable securities totaled $79.43 million at June 30, 2026.
• Enrollment completed for the primary analysis in the Phase 2 PYNNACLE ovarian cancer cohort; initial accelerated-approval NDA filing targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350448), on August 14, 2026, and is solely responsible for the information contained therein.